GlassScriptPhysician profile
Kyle H Lancaster
NPI 1780312496
$1,447.60
in general payments reported to CMS, 2019-2025
26 companies · $878 in 2025
The $878 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $161 · 2023: $75.95 · 2024: $332 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $236.18 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.47 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $150.88 | 2025 | Breztri, Airsupra, Farxiga |
| Kowa Pharmaceuticals America, INC. | $139.02 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $119.65 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $62.93 | 2025 | |
| Glaxosmithkline, LLC. | $57.28 | 2022-2023 | Shingrix, Bexsero, Arexvy |
| Philips North America LLC | $48.34 | 2022-2023 | |
| Corcept Therapeutics | $47.84 | 2025 | Korlym |
| Ardelyx, INC. | $45.89 | 2025 | Ibsrela |
| Lundbeck LLC | $37.13 | 2025 | Rexulti |
| Dexcom, INC. | $26.85 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $25.14 | 2024 | |
| Xeris Pharmaceuticals, INC. | $24.57 | 2024 | Gvoke Hypopen |
| Abbvie INC. | $24.19 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $22.63 | 2022 | |
| Biogen, INC. | $21.17 | 2025 | Leqembi |
| Lilly USA, LLC | $19.26 | 2025 | Kisunla |
| Janssen Pharmaceuticals, INC | $18.43 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $17.33 | 2025 | |
| Esperion Therapeutics, INC. | $16.82 | 2025 | Nexletol |
| Shield Therapeutics INC | $16.52 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.39 | 2024 | Jardiance |
| Medicure Pharma INC. | $13.77 | 2025 | Zypitamag |
| Astellas Pharma US INC | $13.63 | 2023 | Cresemba |
| Merck Sharp & Dohme LLC | $13.29 | 2024 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.